<?xml version="1.0" encoding="UTF-8"?>
<p>In the prevention of fibrosis, it is important to reduce the viral load and hence the duration of viral pneumonia. Development of efficacious therapeutic strategies requires the pursuit of at least one of the three concepts: clinical tests of currently known antiviral agents [
 <xref rid="B91-jcm-09-01917" ref-type="bibr">91</xref>,
 <xref rid="B92-jcm-09-01917" ref-type="bibr">92</xref>], usage of molecular libraries and databases [
 <xref rid="B92-jcm-09-01917" ref-type="bibr">92</xref>,
 <xref rid="B93-jcm-09-01917" ref-type="bibr">93</xref>] and target therapy to disrupt the functioning of the virus [
 <xref rid="B92-jcm-09-01917" ref-type="bibr">92</xref>,
 <xref rid="B94-jcm-09-01917" ref-type="bibr">94</xref>]. These methods led to research on therapeutic agents, out of which hydroxychloroquine and remdesivir seem to be the most promising ones.
</p>
